HONG KONG--(BUSINESS WIRE)--May 6, 2019--
Claves Life Sciences Limited, a wholly owned subsidiary of Aptorum Group
Limited ("Aptorum") (Nasdaq: APM), is excited to announce the
establishment of a novel therapeutic platform for the treatment of
various diseases via modulation of the chemical signaling relating to
gut microbiota. The role of gut microbiota in the pathogenesis of
various diseases has been under the spotlight recently. It has been
demonstrated that gut microbiota is related to major diseases such as
metabolic and cardiovascular diseases1,2, cancer3,
neurodegenerative diseases4, etc.
“With the continuous discovery of the role played by gut microbiota in
various diseases, we believe that novel therapeutic targets will be
subsequently identified and defined. As a result, we believe that the
therapeutic potential of our platform is unlimited at present and for
the future", expressed by Mr. Ian Huen, the CEO of Aptorum. Through our
collaboration with local universities, our initial focus is currently on
metabolic and cardiovascular diseases. We are targeting to move our drug
candidates to Ph 1 clinical trial by 2020 - 2021.
1Nature Communications 8: 845 (2017)
2BMB Rep. 2016 Oct 31; 49(10): 536–541
3https://www.bloomberg.com/news/articles/2016-03-14/how-gut-bacteria-are-shaking-up-cancer-research
4https://www.bbc.com/news/health-46050744
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company
dedicated to developing and commercializing a broad range of therapeutic
and diagnostic technologies to tackle unmet medical needs. Aptorum Group
is pursuing therapeutic and diagnostic projects in neurology, infectious
diseases, gastroenterology, oncology and other disease areas as well as
non-therapeutic areas such as surgical robotics and the operations of
its medical clinic in Hong Kong, Talem Medical, with the initial focus
on treatment of chronic diseases resulting from modern sedentary
lifestyles and aging population.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
About Claves Life Sciences Limited
Claves Life Sciences Limited is a wholly-owned therapeutics subsidiary
of Aptorum Group Limited. Claves focuses on the clinical development in
therapeutic candidates related to the field of gastroenterology. The
potential candidates under review and potentially developed focus on the
modulation of gut microbiota derived metabolites, for preventing or
treating diseases. Claves is also exploring a gut microbiota modulation
platform that can generate novel custom candidates capable of
fine-tuning levels of gut metabolites, potentially treating a wide range
of medical conditions.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group Limited
and its future expectations, plans and prospects that constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. For this purpose, any
statements contained herein that are not statements of historical fact
may be deemed to be forward-looking statements. In some cases, you can
identify forward-looking statements by terms such as “may,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “target,”
“projects,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential,” or “continue,” or the negative of these terms or other
similar expressions. Aptorum Group has based these forward-looking
statements largely on its current expectations and projections about
future events and trends that it believes may affect its business,
financial condition and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions including,
without limitation, risks related to its announced management and
organizational changes, the continued service and availability of key
personnel, its ability to expand its product assortments by offering
additional products for additional consumer segments, the company’s
anticipated growth strategies, anticipated trends and challenges in its
business, and its expectations regarding, and the stability of, its
supply chain, and the risks more fully described in Aptorum Group’s Form
20-F and other filings that Aptorum Group may make with the SEC in the
future. Aptorum Group assumes no obligation to update any
forward-looking statements contained in this press release as a result
of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005342/en/
Source: Aptorum Group Limited
Investors:
Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com
Media:
Tel:
+ 852 2117 6611
Email: info@aptorumgroup.com